- Rare and orphan drug consultancy Open Orphan said it had signed a contract with Carna Bioscience for an in-human clinical trial.

The contract was expected to deliver 'significant' revenue for the company over the next twelve months, Open Orphan said.

Carna was a Japanese company specialising in kinase biology, developing treatments against cancer and immune disorders.

The contract would see Venn Life Sciences, part of Open Orphan, provide Carna with a range of expertise from chemistry manufacturing and controls to clinical trial management as well as biometry, legal and regulatory support.

At 8:13am: [LON:ORPH] share price was +0.15p at 6.45p

Story provided by